EZR and non-small cell lung carcinoma: However, ezrinThr-567 expression was significantly correlated with adverse outcomes with respect to overall survival time, and both ezrin and ezrinThr-567 overexpressions were correlated with shorter survival time in patients with early stage NSCLC.